Coverage dated November 10, 2023 to November 12, 2023
Wegovy weight-loss drug reduced risk of serious heart problems by 20%, study finds
Headline from CBS News, on the newest of 2 developments
A new study from drugmaker Novo Nordisk found that its weight-loss drug Wegovy can reduce the risk of heart problems in people without diabetes, which could change the way doctors treat certain heart patients.
CBS News's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
Developments in this update
2 dated developments, oldest first, newest marked. Each is named by one outlet's own headline; open its reports to see every outlet that covered it.
Novo Nordisk's weight loss drug Wegovy slashes risk of serious heart events
Headline from NBC10 Philadelphia ·
Newest
Wegovy weight-loss drug reduced risk of serious heart problems by 20%, study finds
The findings could expand use of Wegovy and help Novo maintain its lead over Eli Lilly, whose competing weight-loss drug Zepbound was just approved in the U.S.
The popular weight-loss drug Wegovy reduced the risk of serious heart problems by 20% in a large, international study that experts say could change the way doctors treat certain heart patients.
A first-of-its-kind clinical trial found that the weight loss drug lowered the risk of heart attack and stroke in people with heart disease and obesity.
By Meg Tirrell, CNN (CNN) — Results from a landmark clinical trial this summer suggested, for the first time, that a medication given for weight loss alone could reduce the risk of heart attack, stroke or heart-related death in people with cardiovascular disease, bolstering physicians’ excitement ab…
PHILADELPHIA — Novo Nordisk on Saturday said the heart-protective benefits of its wildly popular Wegovy obesity treatment are due to more than weight loss alone, according to new data presented
Novo Nordisk A/S unveiled details from a closely watched study that support use of Wegovy, its blockbuster weight-loss drug, to cut heart attacks and strokes in obesity patients with a history of cardiovascular disease.
“It moves from a kind of therapy that reduces body weight to a therapy that reduces cardiovascular events,” said Dr. Michael Lincoff, the study’s lead author and a heart expert at the Cleveland Cli…
Novo Nordisk A/S gained another $14.5 billion after a key study backed the use of Wegovy, its blockbuster weight-loss drug, to cut heart attacks and deaths in people with obesity and a history of cardiac disease.
A study showing that Novo Nordisk's Wegovy has the ability to reduce the risk of serious heart problems in some patients by 20% was published in the New England Journal of Medicine.
A new study from drugmaker Novo Nordisk found that its weight-loss drug Wegovy can reduce the risk of heart problems in people without diabetes, which could change the way doctors treat certain heart patients.
Wegovy was found to cut the risk of serious heart events by 20%—Novo Nordisk has now asked the U.S. FDA to reflect the heart benefits in the drug's label.
Novo Nordisk reported a study indicated its diabetes and weight-loss drug, Wegovy, helped reduce risks of heart attack, stroke, or death from cardiovascular disease.
Identical headlines usually mean shared wire copy. They are counted as separate articles but are not independent confirmation.
